Itasetron. DAU 6215, U 98079.
D000818:Animals; D000932:Antiemetics / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects; D001562:Benzimidazoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018849:Controlled Clinical Trials as Topic; D006801:Humans; D015337:Multicenter Studies as Topic; D011985:Receptors, Serotonin / Q000187:drug effects; D044406:Receptors, Serotonin, 5-HT3; D012702:Serotonin Antagonists / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
D000932:Antiemetics; D000970:Antineoplastic Agents; D001562:Benzimidazoles; D019086:Bridged Bicyclo Compounds, Heterocyclic; D011985:Receptors, Serotonin; D044406:Receptors, Serotonin, 5-HT3; D012702:Serotonin Antagonists; C070191:itasetron